The French National Agency for the Safety of Medicines and Health Products (ANSM) has confirmed a price increase for the drug EXACYL (tranexamic acid), a critical treatment used to control severe bleeding. The agency stated the adjustment is a direct response to significant pressures on the drug's supply chain, which have increased production and distribution costs.
EXACYL is an antifibrinolytic agent commonly used in surgical settings and for treating traumatic hemorrhages. The ANSM emphasized that ensuring the continued availability of this essential medicine for patients and hospitals was a primary factor in authorizing the price revision. The exact percentage of the increase was not specified in the agency's public communications.
This move follows broader concerns about drug shortages and pricing within the French and European healthcare systems. The ANSM maintains that such pricing decisions are carefully evaluated to balance market sustainability with public health needs, particularly for products with few or no therapeutic alternatives.
